Importance: Data from seroepidemiologic surveys measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure in diverse communities and ascertaining risk factors associated with infection are important to guide future prevention strategies. Objective: To assess the prevalence of previous SARS-CoV-2 infection across Virginia and the risk factors associated with infection after the first wave of coronavirus disease 2019 (COVID-19) infections in the US. Design, Setting, and Participants: In this statewide cross-sectional surveillance study, 4675 adult outpatients presenting for health care not associated with COVID-19 in Virginia between June 1 and August 14, 2020, were recruited to participate in a questionnaire and receive venipuncture to assess SARS-CoV-2 serology. Eligibility was stratified to meet age, race, and ethnicity quotas that matched regional demographic profiles. Main Outcomes and Measures: The main outcome was SARS-CoV-2 seropositivity, as measured by the Abbott SARS-CoV-2 immunoglobulin G assay. Results: Among 4675 adult outpatients (mean [SD] age, 48.8 [16.9] years; 3119 women [66.7%]; 3098 White [66.3%] and 4279 non-Hispanic [91.5%] individuals) presenting for non-COVID-19-associated health care across Virginia, the weighted seroprevalence was 2.4% (95% CI, 1.8%-3.1%) and ranged from 0% to 20% by zip code. Seroprevalence was notably higher among participants who were Hispanic (10.2%; 95% CI, 6.1%-14.3%), residing in the northern region (4.4%; 95% CI, 2.8%-6.1%), aged 40 to 49 years (4.4%; 95% CI, 1.8%-7.1%), and uninsured (5.9%; 95% CI, 1.5%-10.3%). Higher seroprevalence was associated with Hispanic ethnicity (adjusted odds ratio [aOR], 3.56; 95% CI, 1.76-7.21), residence in a multifamily unit (aOR, 2.55; 95% CI, 1.25-5.22), and contact with an individual with confirmed COVID-19 infection (aOR, 4.33; 95% CI, 1.77-10.58). The sensitivity of serology results was 94% (95% CI, 70%-100%) among those who reported receiving a previous polymerase chain reaction test for COVID-19 infection. Among 101 participants with seropositive results, 67 individuals (66.3%) were estimated to have asymptomatic infection. These data suggested a total estimated COVID-19 burden that was 2.8-fold higher than that ascertained by PCR-positive case counts. Conclusions and Relevance: This large statewide serologic study estimated that 2.4% of adults in Virginia had exposure to SARS-CoV-2, which was 2.8-fold higher than confirmed case counts. Hispanic ethnicity, residence in a multifamily unit, and contact with an individual with confirmed COVID-19 infection were significant risk factors associated with exposure. Most infections were asymptomatic. As of August 2020, the population in Virginia remained largely immunologically naive to the virus.
Importance: Data from seroepidemiologic surveys measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure in diverse communities and ascertaining risk factors associated with infection are important to guide future prevention strategies. Objective: To assess the prevalence of previous SARS-CoV-2 infection across Virginia and the risk factors associated with infection after the first wave of coronavirus disease 2019 (COVID-19) infections in the US. Design, Setting, and Participants: In this statewide cross-sectional surveillance study, 4675 adult outpatients presenting for health care not associated with COVID-19 in Virginia between June 1 and August 14, 2020, were recruited to participate in a questionnaire and receive venipuncture to assess SARS-CoV-2 serology. Eligibility was stratified to meet age, race, and ethnicity quotas that matched regional demographic profiles. Main Outcomes and Measures: The main outcome was SARS-CoV-2 seropositivity, as measured by the Abbott SARS-CoV-2 immunoglobulin G assay. Results: Among 4675 adult outpatients (mean [SD] age, 48.8 [16.9] years; 3119 women [66.7%]; 3098 White [66.3%] and 4279 non-Hispanic [91.5%] individuals) presenting for non-COVID-19-associated health care across Virginia, the weighted seroprevalence was 2.4% (95% CI, 1.8%-3.1%) and ranged from 0% to 20% by zip code. Seroprevalence was notably higher among participants who were Hispanic (10.2%; 95% CI, 6.1%-14.3%), residing in the northern region (4.4%; 95% CI, 2.8%-6.1%), aged 40 to 49 years (4.4%; 95% CI, 1.8%-7.1%), and uninsured (5.9%; 95% CI, 1.5%-10.3%). Higher seroprevalence was associated with Hispanic ethnicity (adjusted odds ratio [aOR], 3.56; 95% CI, 1.76-7.21), residence in a multifamily unit (aOR, 2.55; 95% CI, 1.25-5.22), and contact with an individual with confirmed COVID-19infection (aOR, 4.33; 95% CI, 1.77-10.58). The sensitivity of serology results was 94% (95% CI, 70%-100%) among those who reported receiving a previous polymerase chain reaction test for COVID-19infection. Among 101 participants with seropositive results, 67 individuals (66.3%) were estimated to have asymptomatic infection. These data suggested a total estimated COVID-19 burden that was 2.8-fold higher than that ascertained by PCR-positive case counts. Conclusions and Relevance: This large statewide serologic study estimated that 2.4% of adults in Virginia had exposure to SARS-CoV-2, which was 2.8-fold higher than confirmed case counts. Hispanic ethnicity, residence in a multifamily unit, and contact with an individual with confirmed COVID-19infection were significant risk factors associated with exposure. Most infections were asymptomatic. As of August 2020, the population in Virginia remained largely immunologically naive to the virus.
Authors: Cesar A Lopez; Clark H Cunningham; Sierra Pugh; Katerina Brandt; Usaphea P Vanna; Matthew J Delacruz; Quique Guerra; D Ryan Bhowmik; Samuel J Goldstein; Yixuan J Hou; Margaret Gearhart; Christine Wiethorn; Candace Pope; Carolyn Amditis; Kathryn Pruitt; Cinthia Newberry-Dillon; John L Schmitz; Lakshmanane Premkumar; Adaora A Adimora; Ralph S Baric; Michael Emch; Ross M Boyce; Allison E Aiello; Bailey K Fosdick; Daniel B Larremore; Aravinda M de Silva; Jonathan J Juliano; Alena J Markmann Journal: mSphere Date: 2022-05-19 Impact factor: 5.029
Authors: Abdulla A Damluji; Siqi Wei; Scott A Bruce; Amanda Haymond; Emanuel F Petricoin; Lance Liotta; G Larry Maxwell; Brian C Moore; Rachel Bell; Stephanie Garofalo; Eric R Houpt; David Trump; Christopher R deFilippi Journal: Lancet Reg Health Am Date: 2021-07-29
Authors: Kevin P Conway; Kriti Bhardwaj; Emmanuella Michel; Diana Paksarian; Aki Nikolaidis; Minji Kang; Kathleen R Merikangas; Michael P Milham Journal: medRxiv Date: 2022-03-05
Authors: Anna R Giuliano; Shari Pilon-Thomas; Michael J Schell; Martha Abrahamsen; Jessica Y Islam; Kimberly Isaacs-Soriano; Kayoko Kennedy; Christopher W Dukes; Junmin Whiting; Julie Rathwell; Jonathan A Hensel; Leslie N Mangual; Ernst Schonbrunn; Melissa Bikowitz; Dylan Grassie; Yan Yang Journal: Emerg Infect Dis Date: 2022-01-26 Impact factor: 6.883
Authors: Cesar A Lopez; Clark H Cunningham; Sierra Pugh; Katerina Brandt; Usaphea P Vanna; Matthew J Delacruz; Quique Guerra; Samuel Jacob Goldstein; Yixuan Jacob Hou; Margaret Gearhart; Christine Wiethorn; Candace Pope; Carolyn Amditis; Kathryn Pruitt; Cinthia Newberry-Dillon; John Schmitz; Lakshmanane Premkumar; Adaora A Adimora; Michael Emch; Ross Boyce; Allison E Aiello; Bailey K Fosdick; Daniel B Larremore; Aravinda M de Silva; Jonathan J J Juliano; Alena J Markmann Journal: medRxiv Date: 2021-03-30
Authors: Deborah S Hasin; David S Fink; Mark Olfson; Andrew J Saxon; Carol Malte; Katherine M Keyes; Jaimie L Gradus; Magdalena Cerdá; Charles C Maynard; Salomeh Keyhani; Silvia S Martins; Ofir Livne; Zachary L Mannes; Scott E Sherman; Melanie M Wall Journal: Drug Alcohol Depend Date: 2022-03-03 Impact factor: 4.852